Kornimate/medical-research-clean huggingface dataset:
rehab after hip fracture with wearable device

Conditions: Fracture of Hip

Summary: a randomized control trial, including two intervention arms with different methods for rehabilitation after hip fracture, conducted among persons with the need of rehabilitation in their own home.

the increase of the aging population challenges health care providers. fragility, oste-oporosis, and impaired balance are some major risk factors for hip fracture, an injury causing morbidity, mortality, and loss of independent life. this study aims to study if adding continuous measures of body positions and movements 24 hours a day with an inertial measurement unit (imu) can, compared to standard rehabilitation alone, optimize rehabilitation after hip fracture. the study is designed as a randomized controlled trial. patients with hip fracture that require rehabilitation at home, will be invited to participate in the study. those who accept to participate will randomly be assigned to intervention- or control group. the intervention comprises standard rehabilitation and continuous measures of body positions and movements 24 hours a day with an imu. standard rehabilitation comprises of home-visits by a pt, where an individualized rehabilitation plan is outlined together with the patient. the plan includes individually tailored functional exercises. the plan also includes individually tailored walking exercises, indoor and outdoor when possible. at each home visit, the pt provides feedback to the participant based on the data from the imu, i.e. body positions (time spent in sitting, standing, lying down) and body movements (steps per day, step length, walking speed, sideway deviation during walking). the control group receives standard rehabilitation only. the primary outcome is balance, in terms of postural sway measured with the imu, and functional balance measured with the functional balance test for geriatric patients, secondary outcomes are health-related quality of life, measured with the eq5d, functional independence in everyday activities, measured with the barthel index, fear of falling, measured with the falls efficacy scale international, satisfaction with rehabilitation, measured with a single question, and compliance to the intervention .

Eligibility criteria:
inclusion criteria: * patients with a hip fracture, living in malmö, and who are unable to visit a rehabilitation facility and therefore request treatment at home. another inclusion criterion is the ability to read and understand the swedish language or the ability to understand information through an interpreter. exclusion criteria: * the presence of major neurological diseases that have an impact on balance and walk-ing ability; a diagnosed cognitive disease, or moderate to severe cognitive impairment as assessed by a physiotherapist

Keywords: fracture of hip postural sway balance rehabilitation wearable device
clinical study to evaluate the safety and effectiveness of the rxsight light adjustable lens (lal) in subjects with prior corneal refractive surgery

Conditions: Aphakia; Cataract

Summary: the primary objective of this study is to evaluate, for the visual correction of aphakia, the safety and effectiveness of the rxsight light adjustable lens (lal) and light delivery device (ldd) to reduce postoperative refractive error and improve uncorrected distance visual acuity in eyes with prior corneal refractive surgery. a control group consisting of fellow eyes implanted with a commercially available iol will be used to compare the safety and effectiveness of the lal.


Eligibility criteria:
inclusion criteria: * must sign a written informed consent form and be willing to undergo cataract surgery for the bilateral implantation of an intraocular lens (iol). * between the ages of 40 and 80 inclusive on the day the cataract surgery is performed. * history of laser-assisted in situ keratomileusis (lasik), photorefractive keratectomy (prk), laser-assisted subepithelial keratomileusis (lasek), epi-lasik, or epi-lasek more than 1 year prior in both eyes. * cataract causing reduction in best corrected distance visual acuity (bcdva) to a level of 20/40 or worse with or without a glare source in both eyes. * willing and able to comply with the requirements for study specific procedures and visits. * able to complete a written questionnaire in english. exclusion criteria: * prior history of intacs, rk, ck, ak, phakic iol (icl), refractive lens exchange (rle), or corneal inlay in either eye. * pre-existing macular disease in either eye. * patients with sufficiently dense cataracts that preclude examination of the macula in either eye. * history of uveitis in either eye. * evidence of ectasia in either eye. * previous intraocular surgery in either eye. eyes with previous pterygium excision are permitted as long as the pterygium did not extend more than 2mm onto the cornea from the limbus. * subjects taking systemic medication that may increase sensitivity to uv light. * subjects taking a systemic medication that is considered toxic to the retina such as tamoxifen. * history of ocular herpes simplex virus in either eye.

Keywords: light adjustable lens intraocular lens lal
up-front hematopoietic stem cell transplantation in acute myeloid leukemia patients aged 65-75

Conditions: Acute Myeloid Leukemia, Adult

Summary: patients with acute myeloid leukemia aged 65-75 have a very poor prognosis, irrespective of the treatment strategy, including demethylating agents or conventional chemotherapy. with these approaches, remission rates do not exceed 40%, and overall disease-free survival at 1 year is in the order of 15%. the hypothesis is that up-front allogeneic hematopoietic stem cell transplant will produce a complete remission rate of 60% on day +56-70, and disease-free survival at 1 year of 30%. this is a single arm phase ii study of upfront allogeneic stem cell transplantation, for patients with acute myeloid leukemia aged 65-75: the primary endpoint is a complete remission rate on day +56-70. the secondary endpoint is a 1-year overall disease-free survival of 30%.


Eligibility criteria:
inclusion criteria: * patients aged 65-75 * patients with de novo or secondary acute myeloid leukemia (aml) - intermediate or high risk according to european leukemianet (eln) recommendations 2017 * untreated patients at diagnosis of acute myeloid leukemia - patients may have received treatment for high-risk myelodysplastic syndromes with hypomethylating agents (hma). they should not have received a course of induction chemotherapy to be eligible for this study * haploidentical family stem cell donor or other suitable donors available * fit and unfit patients by geriatric scale assessment * signed informed consent. exclusion criteria: * acute myeloid leukemia good risk according to european leukemianet 2017 * positive serology for human immunodeficiency virus. * serious organ dysfunction: left ventricular ejection fraction \ 5 x the upper limit of normal, or creatinine clearance \<30 ml/min . * life expectancy less than 30 days. * frail patients by geriatric scale assessment
effectiveness and safety of new botanical component-lfco- compared with existing tto in clinical study

Conditions: Acne Vulgaris

Summary: in an 8 week double blind randomized controlled split-face studies, we tried to compare the clinical efficacy, safety and histopathological changes between lactobacillus fermented chamaecypris obtusa (lfco) and existing tea tree oil (tto) basically, this is a split face study - one side of face randomly assigned was applied with lfco and the other side with tto in same patients.

screening of natural compounds for the development of anti-acne therapeutic agents has been steadily required considering various side effects of acne medications.however, previous studies have mainly focused on experimental tests without clinical trials and histopathological analysis. to compare the clinical efficacy, safety and histopathological changes between lactobacillus fermented chamaecypris obtusa (lfco) and existing tea tree oil (tto) total thirty four patients were instructed to apply 5 % lfco to the involved areas of randomly allocated side and 5 % tto extract to the other side for 8 weeks in a double blind split-face clinical trial.

Eligibility criteria:
inclusion criteria: * age 19-45 * active acne lesions in both sides of face * available during study periods exclusion criteria: * pregnancy, mental illness, intake of oral isotretinoin within 6 months, application of the other oral or topical acne medications, chemical peeling or light based treatments within 6 weeks.

Keywords: acne therapeutics clinical trial natural compound lactobacillus fermented chamaecypris obtuse tea tree oil
individualized management for long gap esophageal atresia

Conditions: Esophageal Atresia

Summary: the treatment of long gap esophageal atresia (lgea) in neonates is one of the most challenging congenital malformations in neonatal surgery. usually the proximal and distal segments of the esophagus are too far apart, which leads to primary anastomosis abandoned. thus various techniques have been used including circular and spiral myotomies、foker and kimura elongation and gastrointestinal replacement. they are being widely used but bring more complications and less effectiveness. and considering about the absence of definite guideline for the diagnosis and treatment of lgea worldwide, we prepare to use a preoperative staged stress function procedure for elongation of the proximal and distal segments, then to obtain an exact evaluation of the pouch status to achieve an individualized protocol of diagnosis and treatment utilizing the native esophagus to establish esophageal continuity for patients with lgea.

patients with diagnosis of lgea(gap distance\>3.5cm) will be accepted to the program. after accepted to our center, the patients will feed by gastrostomy tube to keep nutritional status remain well controlled. continuous suction in the upper pouch will be applied to avoid aspiration pneumonia. we will design a bouginage with baroreceptor. then the stress function will be performed as following steps. the designed bouginage will be inserted into the upper esophagus pouch through oral cavity with a certain downward longitudinal force to increase esophageal length by tissue stretch and growth, it will be performed 10-15 minutes each time once/twice a day. while the elongation of distal pouch will be achieved via the gastrostomy using the same bouginage to give upward pressure, the program will be operated under x-ray firstly to avoid injury or false passage formation,it can be performed in the ward thereafter. the gap length and the diameter of the pouch will be evaluated every 1-2 weeks. during the elongation period, continuous upper pouch suctioning and nutritional support were maintained. when the gap distance is short enough，the method of surgery will be decided，including end-to-end anastomosis、livadites、flip-flap and choice of thoracoscopy use. the purpose of the program is to achieve the exact management and treatment for patients with lgea and help promoting the use of the new technology.

Eligibility criteria:
inclusion criteria： * patients with long gap esophageal atresia（lgea）which the gap lenth≥3.5cm； * with（out）tracheoesophageal fistula（tef） exclusion criteria: * patients with lgea which can not accept the staged stress function

Keywords: long gap esophageal atresia
acoustic radiation force impulse (arfi)technology in prediction of liver fibrosis

Conditions: Liver Fibrosis

Summary: background: in patients with chronic liver diseases, liver fibrosis staging is crucial for hazard evaluation of future disease complication development and thus for the optimal decision making on treatment selections.in the era of antiviral and antifibrotic treatments, clinical and research demands are also increasing for non-invasive surveillance of liver fibrosis to evaluate the progression or regression. however, local baseline data on liver stiffness measurement (lsm) using arfi technique is still lacking in taiwan, where viral hepatitides are highly endemic. aim: using the arfi elastosonography, we are dedicated to the aims to recruit patients based on strict but appropriate criteria, to complete the correlation and validity studies between arfi quantification and the referenced metavir fibrosis scoring and to conduct subsequent innovative studies on liver diseases. materials and methods: we plan to perform the arfi quantification for each hbv or hcv-infected patient immediately followed by priorly scheduled conventional liver biopsy for metavir scoring during the same session of examination. statistics: the first year's study using arfi will focus on the correlation testings and validity studies using receiver operating characteristics.

contribution and future works: using the arfi quantification either as a causal factor or as a outcome, we can conduct future analyses ranging from validations, regressions to prospective time-to-event analysis among our cohorts.

Eligibility criteria:
inclusion criteria: * infected with hbv only or hcv only exclusion criteria: * concurrent hbv-hcv infection, etc.

Keywords: acoustic radiation force impulse (arfi) virtual touch quantification (vtq) liver stiffness measurement (lsm) liver fibrosis cirrhosis hepatitis b hepatitis c
comfort and quality of life of older cardiac patients

Conditions: Cardiovascular Diseases; Quality of Life

Summary: the aims of the study were to determine the comfort and quality of life, to examine the relationship between them, and to identify factors that affect the comfort and quality of life in older cardiac patients. the cross-sectional study was conducted in the inpatient cardiology clinic of a university hospital in bolu. overall, 209 patients, who met the inclusion criteria, consisted of the sample. a descriptive characteristics form, the general comfort scale and quality of life index cardiac version-iv was used to collect data. the study was reported in the strengthening the reporting of observational studies in epidemiology statement. mean of the general comfort scale scores was 16.18±0.82, and the mean of the turkish quality of life index (qli) cardiac version-iv scores was 2.97±0.39. physical, psycho-spiritual, environmental, and sociocultural comfort levels associated with both the general qli cardiac version-iv scale and sub-dimensions of its (p\<0.05). the location of residence, perception of income status, frequency of hospitalization, dietary adherence, routine health control, and dizziness were the independent variables associated with the general comfort and quality of life scale (p\<0.05).


Eligibility criteria:
inclusion criteria: * were to be 65 years and older, * have a diagnosis of cvds, * speak and understand turkish, * can communicate verbally. exclusion criteria: * hearing impairments and cognitive limitations

Keywords: comfort quality of life cardiac patients nursing older patients
study to determine the safety of two applications of pep005 topical gel to actinic keratoses

Conditions: Actinic Keratosis

Summary: the purpose of this study is to determine whether topical application of pep005 is safe for the treatment of actinic keratoses.


Eligibility criteria:
inclusion criteria: * male or female patients * at least five individual ak lesions on the arms, shoulders, chest, face and/or scalp exclusion criteria: * a cosmetic or therapeutic procedure: * within 10 cm of the selected ak lesions during the 3 months prior to study entry or * anywhere during the 4 weeks prior to study entry or anticipated treatment during the study * treatment with 5-fluorouracil, imiquimod, diclofenac or photodynamic therapy: * of lesions located within 10 cm of the selected ak lesions during the 3 months prior to study entry or * anywhere during the 4 weeks prior to study entry or anticipated treatment during the study * use of acid-containing products, topical retinoids or light chemical peels within 10 cm of the selected ak lesions during the 3 months prior to study entry, or anticipated treatment in this same area during the study * treatment with immuno-modulators, cytotoxic drugs, or interferon/interferon inducers during the 4 weeks prior to study entry or anticipated treatment during the study * treatment with psoralen plus uva or use of uvb therapy during the 6 months prior to study entry or anticipated treatment during the study * use of systemic retinoids during the 6 months prior to study entry or anticipated treatment during the study * anticipated excessive or prolonged exposure to ultraviolet light or use of topical salves, creams or ointments to the selected ak lesions during the study * females of childbearing potential

Keywords: actinic keratosis solar keratosis ak sun spots pep005 topical dermatology
backtracking leukemia-typical somatic mutations in cord blood

Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia

Summary: a comprehensive mechanistic and epidemiological study to obtain banked cord blood samples from consecutive childhood leukemia patients enrolled in the cog project:everychild (apec14b1) study. will attempt to backtrack the initiating genomic alteration identified in the matched diagnostic leukemia sample and molecularly characterize pre-leukemic cells. the ultimate goal of this research is to pinpoint the cell of origin of leukemogenic alterations formed in utero, elucidating the etiology of these initiating mutations (as opposed to frank leukemia), and devising a test for circulating pre-leukemia that can be applied on a population-wide basis.

objectives: primary aim 1: to obtain stored cord blood and dried bloodspots of pediatric leukemia patients in project:everychild. secondary aim 2: to conduct preliminary backtracking and characterization of all- and aml-typical somatic mutations in cord blood and dried bloodspots. outline: accrue patients with all and aml who indicate having banked cord blood at birth through the apec14b1 intake questionnaire

Eligibility criteria:
inclusion criteria: * the patient must have a diagnosis of acute lymphoblastic leukemia (all) or acute myeloid leukemia (aml). * stored diagnostic pre-treatment samples corresponding to the patient's original diagnosis of leukemia must be available for request from either the cog biopathology center or a treating institution * the patient must be enrolled on apec14b1 with consent to future contact and indicate that cord blood was stored at birth in the apec14b1 registry intake data. * the patient must also have been registered with cog by a north american (limited to the u.s. and canada) member institution. * ≤ 25 years old at the time of original diagnosis with all or aml * the patient must be able to understand written and spoken english or spanish * all patients must provide their consent/assent, as appropriate, and for patients under the age of majority at least one parent or legal guardian must provide consent as well * all institutional, fda, and nci requirements for human studies must be met exclusion criteria: * patients who responded that cord blood was not stored at birth are excluded. patients without stored diagnostic, pre-treatment leukemia samples at either the cog biopathology center or their treating institution are excluded.
cardiovascular magnetic resonance guided open artery trial for revascularization of late presenting st elevation myocardial infarction

Conditions: STEMI

Summary: patients with stemi are usually treated with primary pci in contemporary practice. however, primary pci is currently deemed unbeneficial or potentially harmful in patients presenting late after a stemi. there is limited data to suggest that patients who may have viable myocardium despite presenting late with a stemi may derive benefit from pci, which may be denied in current practice. cmr imaging is the reference modality for assessment of left ventricular function and myocardial viability. this feasibility study will randomise late presenting stemi patients with cmr documented viability to pci plus optimal medical therapy (omt) versus omt alone. the investigator hypothesises that pci in this cohort will improve left ventricular remodelling and function. favourable results will lead to an adequately powered multi-centre trial with the potential to improve the management of late resenting stemi patients and impact on clinical practice guidelines.

stable patients with late presenting stemi will be prospectively recruited into this study from 5 large primary pci centres in the uk. ethical approval from a research ethics committee and written informed consent from all participants will be obtained. recruited patients will receive baseline cmr to detect viability within 7 days of index admission or coronary angiogram. patients with non-viable myocardium will be treated with standard clinical care and form part of the registry arm. patients with viable myocardium will be randomised to revascularization with omt vs omt alone. pci will be performed according to standard techniques using newer generation drug eluting stents. all patients will recieve dual anti-platelet treatment for 12 months, or as per local practice guidelines. other treatments will be given according to evidence based guidelines. revascularization wth cabg can also be considered, based on mdt decision. the feasibility study will randomise 60 patients (30 in pci and 30 in omt group). oat-nuc trial showed that 70% late presenting stemi may have viability. therefor, recruiting 90 patients for baseline cmr may provide 60 patients to randomise. the results of this feasibility study will inform the investigator of the numbers needed for an adequately powered multi-centre clinical trial.

Eligibility criteria:
inclusion criteria: * stemi patients presenting \>12 hours, and within 28 days, after symptom onsent. * stable patients with no on-going features of ischaemia (chest pain, dynamic ecg changes) exclusion criteria: * inability to give informed consent * standard cmr contra-indications * haemodynamic instability (requiring on-going intravenous therapy or respiratory support) * previous coronary artery bypass grafting and cardiomyopathy * estimated glomerular filtration rate \<30ml/min/1.73m2 * end-stage malignancy or expected life expectancy of less than 12 months.
gastric banding after failed gastric bypass

Conditions: Obesity

Summary: the safety and efficacy of the adhesix bioring adjustable gastric band will be assessed in patients after failed rygb.


Eligibility criteria:
inclusion criteria: * patient must sign the informed consent form prior to the index-procedure. * patient with failed rygb defined as patients with ewl \<50%. exclusion criteria: * patient has a life expectancy of less than 2 year. * patient who is most likely expected not to be compliant with the proposed follow-up visits.